We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+3.59%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$428M
AUM Growth
+$49.7M
Cap. Flow
+$59.6M
Cap. Flow %
13.93%
Top 10 Hldgs %
96.18%
Holding
13
New
1
Increased
7
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$21.2M
2
EXEL icon
Exelixis
EXEL
+$9.43M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$9.39M
4
VRNA
Verona Pharma
VRNA
+$7.99M
5
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$4.68M

Top Sells

Rank Stock Value
1
YMAB
Y-mAbs Therapeutics
YMAB
+$70.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.11B
$124M 29.05%
10,360,945
– –
ALIM
2
DELISTED
Alimera Sciences
ALIM
$93.6M 21.87%
16,835,154
– –
ANIK icon
3
Anika Therapeutics
ANIK
$203M
$36.4M 8.5%
1,435,993
– –
EXEL icon
4
Exelixis
EXEL
$14.1B
$34.3M 8.01%
1,525,730
+425,000
+39% +$9.43M
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.36B
$28.4M 6.64%
4,598,737
+3,840,235
+506% +$21.2M
VRNA
6
DELISTED
Verona Pharma
VRNA
$26.7M 6.23%
1,843,756
+547,309
+42% +$7.99M
EOLS icon
7
Evolus
EOLS
$377M
$23.5M 5.5%
2,167,790
+278,909
+15% +$3.43M
AGIO icon
8
Agios Pharmaceuticals
AGIO
$2.36B
$22.2M 5.19%
514,711
+30,000
+6% +$1.08M
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$400M
$13.5M 3.16%
1,042,889
+184,819
+22% +$2.49M
MLYS icon
10
Mineralys Therapeutics
MLYS
$2.39B
$8.73M 2.04%
+745,758
New +$9.39M
YMAB
11
DELISTED
Y-mAbs Therapeutics
YMAB
$7.03M 1.64%
582,078
-5,198
-0.9% -$70.2K
NBP
12
NovaBridge Biosciences American Depositary Shares
NBP
$206M
$5.64M 1.32%
3,374,791
+2,618,253
+346% +$4.68M
OTLK icon
13
Outlook Therapeutics
OTLK
$207M
$3.69M 0.86%
500,000
– –

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Caligan Partners held 13 positions worth $428M, up 13% from $378M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Caligan Partners deployed $59.6M of net new capital in Q2 2024, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Mineralys Therapeutics: 745,758 shares worth $8.73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Y-mAbs Therapeutics, an estimated $70.2K trimmed.

  • Caligan Partners's largest Q2 2024 buy was Mineralys Therapeutics: 745,758 shares worth $8.73M.
  • Caligan Partners added most to BioCryst Pharmaceuticals in Q2 2024, an estimated $21.2M increase.
  • Caligan Partners's biggest Q2 2024 reduction was Y-mAbs Therapeutics, cutting an estimated $70.2K.
  • Caligan Partners's ten largest holdings make up 96% of its $428M portfolio in Q2 2024.
  • Caligan Partners opened 1 new position and closed 0 in Q2 2024.
  • Caligan Partners's portfolio value rose 13% quarter-over-quarter to $428M.

Based on Caligan Partners's 13F filing for Q2 2024, filed 14 Aug 2024.